Birdwatch Note
2024-10-06 04:21:39 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
ファイザーはドイツの中国系企業との主張がされこれは誤訳ではないですが、勿論ファイザーは米国発祥の米国企業です。 https://www.pfizer.co.jp/pfizer/company/history-us この比喩?は中国の復星医薬(fosun pharma)と契約したからという事のようですが、復西はBiontechとライセンス契約を結び20年3月に中国本土香港マカオ、台湾でビオンテックのmRNAワクチンを独占的に生産販売する権利を取得したにすぎません。 https://toyokeizai.net/articles/-/428527?display=b 10億の生産ができる工場という動画の工場も21年月に上記地域への供給を目指されましたが https://en.wikipedia.org/wiki/BioNTech その後、香港マカオで承認される一方で本土では全海外ワクチンの承認は難航したという経緯です https://www.nytimes.com/2022/02/18/business/china-coronavirus-vaccines.html
Written by 41A6243EF0C5E2F69F5A0D4006A468F4F7CBEC237CAE6ACCC5FB56ED687492FE
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1842583582562480338
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1842782247256268819
- noteId - 1842782247256268819
- participantId -
- noteAuthorParticipantId - 41A6243EF0C5E2F69F5A0D4006A468F4F7CBEC237CAE6ACCC5FB56ED687492FE Participant Details
- createdAtMillis - 1728188499641
- tweetId - 1842583582562480338
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 1
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- ファイザーはドイツの中国系企業との主張がされこれは誤訳ではないですが、勿論ファイザーは米国発祥の米国企業です。 https://www.pfizer.co.jp/pfizer/company/history-us この比喩?は中国の復星医薬(fosun pharma)と契約したからという事のようですが、復西はBiontechとライセンス契約を結び20年3月に中国本土香港マカオ、台湾でビオンテックのmRNAワクチンを独占的に生産販売する権利を取得したにすぎません。 https://toyokeizai.net/articles/-/428527?display=b 10億の生産ができる工場という動画の工場も21年月に上記地域への供給を目指されましたが https://en.wikipedia.org/wiki/BioNTech その後、香港マカオで承認される一方で本土では全海外ワクチンの承認は難航したという経緯です https://www.nytimes.com/2022/02/18/business/china-coronavirus-vaccines.html
Note Ratings
rated at | rated by | |
2024-10-09 00:36:43 -0500 | Rating Details | |
2024-10-07 07:19:06 -0500 | Rating Details | |
2024-10-06 11:54:30 -0500 | Rating Details | |
2024-10-06 10:04:05 -0500 | Rating Details | |
2024-10-06 08:25:01 -0500 | Rating Details | |
2024-10-06 05:29:07 -0500 | Rating Details | |
2024-10-06 01:02:19 -0500 | Rating Details | |
2024-10-06 01:01:56 -0500 | Rating Details | |
2024-10-06 00:50:56 -0500 | Rating Details | |
2024-10-06 00:35:52 -0500 | Rating Details | |
2024-10-06 00:22:26 -0500 | Rating Details | |
2024-10-06 00:11:48 -0500 | Rating Details | |
2024-10-06 00:08:27 -0500 | Rating Details | |
2024-10-05 23:57:22 -0500 | Rating Details | |
2024-10-06 23:12:34 -0500 | Rating Details | |
2024-10-06 21:50:00 -0500 | Rating Details | |
2024-10-06 21:06:49 -0500 | Rating Details | |
2024-10-06 11:30:05 -0500 | Rating Details | |
2024-10-06 08:26:15 -0500 | Rating Details | |
2024-10-06 06:09:17 -0500 | Rating Details | |
2024-10-06 04:07:18 -0500 | Rating Details | |
2024-10-06 03:42:39 -0500 | Rating Details | |
2024-10-06 03:29:02 -0500 | Rating Details | |
2024-10-06 02:32:24 -0500 | Rating Details | |
2024-10-06 00:54:18 -0500 | Rating Details | |
2024-10-06 00:44:25 -0500 | Rating Details | |
2024-10-06 00:03:17 -0500 | Rating Details | |
2024-10-05 23:57:54 -0500 | Rating Details | |
2024-10-05 23:54:32 -0500 | Rating Details | |
2024-10-05 23:54:14 -0500 | Rating Details | |
2024-10-05 23:47:42 -0500 | Rating Details | |
2024-10-05 23:40:38 -0500 | Rating Details | |
2024-10-08 21:07:07 -0500 | Rating Details | |
2024-10-08 17:18:27 -0500 | Rating Details | |
2024-10-06 17:30:12 -0500 | Rating Details | |
2024-10-06 09:58:58 -0500 | Rating Details | |
2024-10-06 06:53:15 -0500 | Rating Details | |
2024-10-06 03:49:48 -0500 | Rating Details | |
2024-10-06 02:27:11 -0500 | Rating Details | |
2024-10-06 02:03:16 -0500 | Rating Details | |
2024-10-06 01:53:19 -0500 | Rating Details | |
2024-10-06 01:27:22 -0500 | Rating Details | |
2024-10-06 00:57:08 -0500 | Rating Details | |
2024-10-06 00:50:49 -0500 | Rating Details | |
2024-10-06 00:38:57 -0500 | Rating Details | |
2024-10-06 00:32:16 -0500 | Rating Details | |
2024-10-06 00:06:05 -0500 | Rating Details | |
2024-10-06 00:05:43 -0500 | Rating Details | |
2024-10-05 23:55:32 -0500 | Rating Details | |
2024-10-05 23:48:07 -0500 | Rating Details | |
2024-10-05 23:31:07 -0500 | Rating Details | |
2024-10-05 23:24:43 -0500 | Rating Details | |
2024-10-18 11:51:01 -0500 | Rating Details | |
2024-10-08 20:29:44 -0500 | Rating Details | |
2024-10-08 17:59:20 -0500 | Rating Details |